Syros Pharmaceuticals (SYRS) Misses Q1 EPS by 9c

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q1 EPS of ($0.48), $0.09 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $0 versus the consensus estimate of $4.05 million.

“Our priorities for 2018 are advancing our first-in-class drug candidates SY-1425 and SY-1365, leveraging our leading gene control platform to continue fueling our pipeline, and building on our strong financial position and company fundamentals,” said Nancy Simonian, M.D., Chief Executive Officer of Syros. “We have made terrific progress on all three fronts this year, presenting preclinical data that support the planned expansion of our Phase 1 trial of SY-1365 into ovarian cancer, entering into a collaboration with Incyte that applies our platform to diseases beyond our current areas of focus, and fortifying our financial position with a successful public offering. We continue to build momentum as we prepare for our planned data readouts in the fourth quarter of this year for both SY-1425 and SY-1365, and we remain focused on executing with excellence as we strive to build a great and enduring company with medicines that make a profound difference for currently underserved patients.”

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• American Express (AXP) down despite beating Q1 estimates on top and bottom lines
• Wipro (WIT) Tops Q1 EPS by 1c
• Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1